Abeona Therapeutics Inc: Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa

-- First gene therapy RMAT designation for Epidermolysis Bullosa
  -- Enables accelerated approval path and real world data usage

NEW YORK and CLEVELAND, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics
Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused
on developing novel cell and gene therapies for life-threatening rare genetic
diseases, announced today that the US Food and Drug Administration (FDA) has
granted the Regenerative Medicine Advanced Therapy (RMAT) designation to
EB-101, the Company's gene-corrected autologous cell therapy product for
patients with recessive dystrophic epidermolysis bullosa (RDEB). 

"EB-101 is an autologous gene-corrected cell therapy approach that utilizes a
patient's own cells and genetically re-engineers them to produce the missing
collagen protein, which helps hold skin on to the body. This reduces the number
of painful blisters caused by injury and has demonstrated improved wound
healing in our Phase 1/2 clinical trial for over 2 years," said Timothy J.
Miller, Ph.D., President and CEO of Abeona. "The receipt of the RMAT and
Breakthrough designations, both over the last six months, reaffirms the
significance of the EB-101 clinical trial results and the need to advance
promising therapies in areas of considerable unmet medical need. We are pleased
that the FDA granted the RMAT designation, which will help accelerate the
development of EB-101, and look forward to continuing our collaborative
discussions in defining the pathway forward for the Phase 3 trial set to begin
later this year." 

Established under the 21st Century Cures Act, the RMAT designation is an
expedited program for the advancement and approval of regenerative medicine
products where preliminary clinical evidence indicates the potential to address
unmet medical needs for life-threatening diseases or conditions. Similar to
Breakthrough Therapy designation, the RMAT allows companies developing
regenerative medicine therapies to work more closely and frequently with the
FDA, and RMAT-designated products may be eligible for priority review and
accelerated approval. In November 2017, the FDA expanded the RMAT designation
for gene therapies. The sponsor of a RMAT therapy that is granted accelerated
approval and is subject to post-approval requirements may, as appropriate,
fulfill such requirements through submission of clinical evidence, clinical
studies, patient registries, or other sources of real world data. For
information on RMAT designation, visit the FDA website: 

https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm537670
.htm 

The Company continues to engage the FDA on its pivotal Phase 3 clinical trial
design, and will provide an update on the program in the coming months. 
Abeona's EB-101 product is an autologous, ex-vivo gene-corrected cell therapy
in which the COL7A1 gene is inserted into a patient's own skin cells
(keratinocytes) for the treatment of the underlying disease in Recessive
Dystrophic Epidermolysis Bullosa. The EB-101 program has been granted
Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease Designations from
the US Food and Drug Administration (FDA) and Orphan Drug Designation from the
European Medicines Agency (EMA). 

About EB-101: In the completed Phase 1/2 clinical trial, EB-101 was
administered to non-healing chronic wounds on each subject and assessed for
wound healing at predefined time points. The trial met the primary endpoints
for safety and efficacy, where wound healing after EB-101 administration was
compared to control untreated wounds from a supporting natural history study
that evaluated 128 patients and approximately 1500 chronic and recurring RDEB
wounds. Secondary endpoints included expression of collagen C7 and restoration
of anchoring fibrils at three and six-months post-administration. Clinical data
demonstrated that EB-101 treated wounds were significantly healed >50% for more
than two years post-administration. The data included: 

Wound healing, defined as >50% closure after EB-101 administration, was
observed in: 
---   100% (42/42 treated wounds, n=7 subjects) at 3 months;
---   90% (38/42 treated wounds, n=7 subjects) at 6 months;
---   83% (20/24 treated wounds, n=4 subjects) at 12 months;
---   88% (21/24 treated wounds, n=4 subjects) at 24 months;
---   100% (6/6 treated wounds, n=1 subject) at 36 months post-administration.

Collagen VII (C7) expression: C7 and morphologically normal NC2 reactive
anchoring fibrils were observed as early as 1 month in EB-101 treated wounds
and have remained for at least two years post-administration. Importantly, data
from a supportive natural history study of approximately 1,500 wounds from 128
patients with RDEB, established by Stanford and EBCare Registry, were also
presented to the FDA. Notably, 13 RDEB patients with a total of 15 chronic
wounds were treated with an allograft product, including Apligraf and
Dermagraft. Of these wounds treated with allografts, only 7% (1/15 treated
wounds) remained healed after 12 weeks, and 0% (0/15 treated wounds) remained
healed after 24 weeks. This is a meaningful finding of the natural history
study, as there are no approved therapies for RDEB patients that demonstrate
significant wound closure after two months post-application. 

About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical
company developing cell and gene therapies for life-threatening rare genetic
diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts)
for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an
adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A
(MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene
therapy for Sanfilippo syndrome type B (MPS IIIB).  Abeona is also developing
ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202
(AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for
epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA)
disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to
gene therapy for rare blood diseases. In addition, Abeona is developing a
proprietary vector platform, AIM, for next generation product candidates.  For
more information, visit www.abeonatherapeutics.com. 

Investor Contact:
Christine Silverstein
SVP, Investor Relations & Finance
Abeona Therapeutics Inc.
[phone]
[e-mail]

Media Contact:
Lynn Granito
Berry & Company Public Relations
[phone]
[e-mail]

This press release contains certain statements that are forward-looking within
the meaning of Section 27a of the Securities Act of 1933, as amended, and that
involve risks and uncertainties. These statements include, without limitation,
our plans for continued development and internationalization of our clinical
programs, that patients will continue to be identified, enrolled, treated and
monitored in the EB-101 clinical trial, and that studies will continue to
indicate that EB-101 is well-tolerated and may offer significant improvements
in wound healing. These statements are subject to numerous risks and
uncertainties, including but not limited to continued interest in our rare
disease portfolio, our ability to enroll patients in clinical trials, the
impact of competition; the ability to develop our products and technologies;
the ability to achieve or obtain necessary regulatory approvals; the ability to
secure licenses for any technology that may be necessary to commercialize our
products; the impact of changes in the financial markets and global economic
conditions; and other risks as may be detailed from time to time in the
Company's Annual Reports on Form 10-K and other reports filed by the Company
with the Securities and Exchange Commission. The Company undertakes no
obligations to make any revisions to the forward-looking statements contained
in this release or to update them to reflect events or circumstances occurring
after the date of this release, whether as a result of new information, future
developments or otherwise.